SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

Search

Fagron

Geschlossen

BrancheGesundheitswesen

19.26 0.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.86

Max

19.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

-298K

40M

Verkäufe

13M

443M

KGV

Branchendurchschnitt

17.346

63.778

Dividendenrendite

1.58

Gewinnspanne

9.066

Angestellte

3,828

EBITDA

-4.3M

71M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+20.59% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.58%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

19M

1.4B

Vorheriger Eröffnungskurs

18.74

Vorheriger Schlusskurs

19.26

Nachrichtenstimmung

By Acuity

50%

50%

166 / 386 Ranking in Healthcare

Fagron Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3. Apr. 2025, 22:40 UTC

Wichtige Markttreiber

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3. Apr. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3. Apr. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3. Apr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3. Apr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3. Apr. 2025, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 21:43 UTC

Top News
Ergebnisse

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3. Apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Apr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3. Apr. 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3. Apr. 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3. Apr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3. Apr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3. Apr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3. Apr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3. Apr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3. Apr. 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3. Apr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3. Apr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3. Apr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3. Apr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Fagron Prognose

Kursziel

By TipRanks

20.59% Vorteil

12-Monats-Prognose

Durchschnitt 19.5 EUR  20.59%

Hoch 19.5 EUR

Tief 19.5 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fagron – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Stimmung

By Acuity

166 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.